ArticleCancer cell2019
Genomic and Transcriptomic Profiling of Combined Hepatocellular and Intrahepatic Cholangiocarcinoma Reveals Distinct Molecular Subtypes.
Open access · greenAbstract readComparative StudyMulticenter Study
In one paragraph
Article in Cancer cell, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 178 papers.
0numbers the graph read from it
0cells of the map it votes in
178citing papers in PubMed
31.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
178 citing papers in PubMed, 287 citations in OpenAlex.
- Molecular biomarkers for diagnosis, prognosis, precision therapy, and immunotherapy in cholangiocarcinoma, cHCC-CCA, and HCC.Hepatology communications · 2026Review
- Hepatoid adenocarcinoma of the lung: clinicopathologic and molecular analysis of 17 cases.Virchows Archiv : an international journal of pathology · 2026Article
- Radiogenomics deciphers tumor heterogeneity in hepatocellular carcinoma and combined hepatocellular-cholangiocarcinoma.Discover oncology · 2026Article
- Genomic landscape of cholangiocarcinoma in India: ethnic variants and implications for targeted therapy.BMC cancer · 2026Article
- Systemic therapy for combined hepatocellular-cholangiocarcinoma: a comprehensive review of chemotherapy, immunotherapy, and targeted therapy.Journal of liver cancer · 2026Review
- Combined hepatocellular-cholangiocarcinoma: a contemporary pathologic and molecular perspective.Journal of liver cancer · 2026Review
- Systemic treatment strategies for combined hepatocellular-cholangiocarcinoma: current evidence and future direction.Journal of liver cancer · 2026Review
- Integrated Multi-Omics Profiling Identifies an Immunotherapy Vulnerable and Prognostic Associated Subtype in Cholangiocarcinoma.Liver cancer · 2026Article
- The inflammatory state of tumor peripheral liver tissue affects hepatocellular carcinoma progression and prognosis.Discover oncology · 2026Article
- Hepatocellular carcinoma-linkediScience · 2026Article
- Arid1a Deficiency Drives Aristolochic Acid-Induced Liver Tumorigenesis through Ctnnb1 Mutation and Defective Nucleotide Excision Repair.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- From organelles to therapy: rethinking combined hepatocellular-cholangiocarcinoma.Frontiers in cell and developmental biology · 2026Review
- Cholangiocarcinoma in the Era of Precision Medicine: Emerging Insights and Therapeutic Strategies.Current pharmaceutical design · 2026Review
- Genetic and molecular advancements in combined hepatocellular-cholangiocarcinoma: Addressing a persistent clinical conundrum.EXCLI journal · 2026Article
- Hepatocellular- cholangiocarcinoma collision tumor: a case report.Frontiers in oncology · 2026Article
- Combined hepatocellular-cholangiocarcinoma: A rare and challenging diagnostic entity - A Case Report.Oncoscience · 2026Article
- Patient-derived d-MMR/MSI phenotype urachal cancer organoids for personalized drug screening.Frontiers in oncology · 2026Article
- MYC-Mediated Functional Manifestation of IDH1 Mutations in Intrahepatic Cholangiocarcinoma Confers Sensitivity to (+)-JQ1.International journal of biological sciences · 2026Article
- Outcomes of Sequential Immune Checkpoint Inhibitor Retreatment After Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma.Journal of gastroenterology and hepatology · 2026Article
- Clonal evolution in gastrointestinal cancers: multi-omics insights into tumor heterogeneity, microenvironmental selection, and translational biomarkers.Frontiers in oncology · 2026Review
118 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
35 authors at 12 institutions in 6 countries.
Ruidong XueBiomedical Pioneering Innovation Center (BIOPIC) and Translational Cancer Research Center, School of Life Sciences, First Hospital, Peking University, Beijing 100871, China.
Lu ChenDepartment of Hepatobiliary Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.
Chong ZhangBiomedical Pioneering Innovation Center (BIOPIC) and Translational Cancer Research Center, School of Life Sciences, First Hospital, Peking University, Beijing 100871, China.
Masashi FujitaLaboratory for Cancer Genomics, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan.
Ruoyan LiBiomedical Pioneering Innovation Center (BIOPIC) and Translational Cancer Research Center, School of Life Sciences, First Hospital, Peking University, Beijing 100871, China.
Shu-Mei YanState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou 510060, China.
Choon Kiat OngLymphoma Genomic Translational Research Laboratory, Division of Cellular and Molecular Research, National Cancer Centre Singapore, Singapore 169610, Singapore.
Xiwen LiaoDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.
Qiang GaoDepartment of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University; Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai 200032, China.
Shota SasagawaLaboratory for Cancer Genomics, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan.
Yanmeng LiBiomedical Pioneering Innovation Center (BIOPIC) and Translational Cancer Research Center, School of Life Sciences, First Hospital, Peking University, Beijing 100871, China.
Jincheng WangBiomedical Pioneering Innovation Center (BIOPIC) and Translational Cancer Research Center, School of Life Sciences, First Hospital, Peking University, Beijing 100871, China.
Hua GuoLaboratory of Cancer Cell Biology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
Qi-Tao HuangState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou 510060, China.
Qian ZhongState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou 510060, China.
Jing TanState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou 510060, China.
Lisha QiDepartment of Pathology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
Wenchen GongDepartment of Pathology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
Zhixian HongDepartment of Hepatobiliary Surgery, Beijing 302 Hospital, Beijing 100039, China.
Meng LiDepartment of Ultrasonography, Beijing 302 Hospital, Beijing 100039, China.
Jingmin ZhaoDepartment of Pathology and Hepatology, Beijing 302 Hospital, Beijing 100039, China.
Tao PengDepartment of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.
Yinying LuComprehensive Liver Cancer Center, Beijing 302 Hospital, Beijing 100039, China.
Kiat Hon Tony LimDepartment of Anatomical Pathology, Singapore General Hospital, Singapore 169608, Singapore.
Arnoud BootCentre for Computational Biology, Duke-NUS Medical School, Singapore 169857, Singapore.
Atushi OnoDepartment of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.
Kazuaki ChayamaDepartment of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.
Zemin ZhangBiomedical Pioneering Innovation Center (BIOPIC) and Translational Cancer Research Center, School of Life Sciences, First Hospital, Peking University, Beijing 100871, China.
Steve George RozenCentre for Computational Biology, Duke-NUS Medical School, Singapore 169857, Singapore.
Bin Tean TehLaboratory of Cancer Epigenome, Division of Medical Sciences, National Cancer Centre Singapore, Singapore 169610, Singapore.
Xin Wei WangLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Hidewaki NakagawaLaboratory for Cancer Genomics, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan. Electronic address: hidewaki@ims.u-tokyo.ac.jp.
Mu-Sheng ZengState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou 510060, China. Electronic address: zengmsh@mail.sysu.edu.cn.
Fan BaiBiomedical Pioneering Innovation Center (BIOPIC) and Translational Cancer Research Center, School of Life Sciences, First Hospital, Peking University, Beijing 100871, China. Electronic address: fbai@pku.edu.cn.
Ning ZhangBiomedical Pioneering Innovation Center (BIOPIC) and Translational Cancer Research Center, School of Life Sciences, First Hospital, Peking University, Beijing 100871, China; Laboratory of Cancer Cell Biology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China. Electronic address: zhangning@bjmu.edu.cn.
Peking University · CNSun Yat-sen University · CN302 Military Hospital of China · CNTianjin Medical University Cancer Institute and Hospital · CNRIKEN Center for Integrative Medical Sciences · JPDuke-NUS Medical School · SGGuangxi Medical University · CNHiroshima University · JPNational Cancer Centre Singapore · SGMinistry of Education of the People's Republic of China · CNNational Cancer Institute · USSingapore General Hospital · SG
Funding
Strategies for improving early detection, diagnosis and treatment of liver cancerZIABC010313 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WANG, XIN WEI · 2009 to 2025
$18.1MIntramural NIH HHS ZIA BC010313
Abstract
We performed genomic and transcriptomic sequencing of 133 combined hepatocellular and intrahepatic cholangiocarcinoma (cHCC-ICC) cases, including separate, combined, and mixed subtypes. Integrative comparison of cHCC-ICC with hepatocellular carcinoma and intrahepatic cholangiocarcinoma revealed that combined and mixed type cHCC-ICCs are distinct subtypes with different clinical and molecular features. Integrating laser microdissection, cancer cell fraction analysis, and single nucleus sequencing, we revealed both mono- and multiclonal origins in the separate type cHCC-ICCs, whereas combined and mixed type cHCC-ICCs were all monoclonal origin. Notably, cHCC-ICCs showed significantly higher expression of Nestin, suggesting Nestin may serve as a biomarker for diagnosing cHCC-ICC. Our results provide important biological and clinical insights into cHCC-ICC.
Indexed as
Gene Expression ProfilingTranscriptomeAsiaBile Duct NeoplasmsBiomarkers, TumorCarcinoma, HepatocellularCholangiocarcinomaDatabases, GeneticFemaleGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansImmunohistochemistryLiver NeoplasmsMaleNeoplasms, Complex and MixedBiomarkers, TumorNES protein, humanNestinAllen and Lisabilinear differentiationclonal originintratumor heterogeneityliver cancermetastatic routemolecular subtypeNestinphenotypic transitionsingle nucleus sequencing
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.